Related references
Note: Only part of the references are listed.Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia
Arlel Berger et al.
CLINICAL THERAPEUTICS (2008)
Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations
Patrick Lefebvre et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 study group trial
John Glaspy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Projecting future drug expenditures - 2006
JM Hoffman et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2006)
Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy
R Waltzman et al.
ONCOLOGIST (2005)
Darbepoetin versus epoetin
JD Herrington
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2005)
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer
LS Schwartzberg et al.
ONCOLOGIST (2004)
Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice
J Patton et al.
ONCOLOGIST (2004)
A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
L Schwartzberg et al.
CLINICAL THERAPEUTICS (2003)
Share Paper
